These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21494698)

  • 1. New conjugate vaccines for the prevention of pneumococcal disease in developing countries.
    Ginsburg AS; Alderson MR
    Drugs Today (Barc); 2011 Mar; 47(3):207-14. PubMed ID: 21494698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries.
    Cohen R; Cohen JF; Chalumeau M; Levy C
    Expert Rev Vaccines; 2017 Jun; 16(6):625-640. PubMed ID: 28409537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.
    Hausdorff WP; Dagan R; Beckers F; Schuerman L
    Vaccine; 2009 Dec; 27(52):7257-69. PubMed ID: 19833248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2008 Nov; 7(9):1367-94. PubMed ID: 18980540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review on the immunogenicity and safety of PCV-13 in infants and toddlers.
    Nunes MC; Madhi SA
    Expert Rev Vaccines; 2011 Jul; 10(7):951-80. PubMed ID: 21806394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?
    Dagan R
    Vaccine; 2008 Jun; 26 Suppl 2():B16-8. PubMed ID: 18793601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of conjugate pneumococcal vaccines on antibiotic resistance.
    Dagan R; Klugman KP
    Lancet Infect Dis; 2008 Dec; 8(12):785-95. PubMed ID: 19022193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake.
    Grabenstein JD; Weber DJ
    Clin Infect Dis; 2014 Mar; 58(6):854-64. PubMed ID: 24344141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013.
    Cho EY; Choi EH; Kang JH; Kim KH; Kim DS; Kim YJ; Ahn YM; Eun BW; Oh SH; Cha SH; Cho HK; Hong YJ; Kim KN; Kim NH; Kim YK; Kim JH; Lee H; Lee T; Kim HM; Lee KS; Kim CS; Park SE; Kim YM; Oh CE; Ma SH; Jo DS; Choi YY; Lee J; Bae GR; Park O; Park YJ; Kim ES; Lee HJ
    J Korean Med Sci; 2016 Jul; 31(7):1082-8. PubMed ID: 27366006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.
    Bliss SJ; O'Brien KL; Janoff EN; Cotton MF; Musoke P; Coovadia H; Levine OS
    Lancet Infect Dis; 2008 Jan; 8(1):67-80. PubMed ID: 17974480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccines.
    Ho CF; Lin TY
    Chang Gung Med J; 2005 Nov; 28(11):765-72. PubMed ID: 16422182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The history of pneumococcal conjugate vaccine development: dose selection.
    Poolman JT; Peeters CC; van den Dobbelsteen GP
    Expert Rev Vaccines; 2013 Dec; 12(12):1379-94. PubMed ID: 24195479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
    Kyaw MH; Jones IG; Campbell H
    Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
    Paradiso P
    Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A Meta-regression Model.
    Le Polain De Waroux O; Flasche S; Prieto-Merino D; Goldblatt D; Edmunds WJ
    Pediatr Infect Dis J; 2015 Aug; 34(8):858-64. PubMed ID: 26075814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.